Article

Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine

2001-04-06

Abstract excerpt

Heterologous prime/boost regimens have the potential for raising high levels of immune responses. Here we report that DNA priming followed by a recombinant modified vaccinia Ankara (rMVA) booster controlled a highly pathogenic immunodeficiency virus challenge in a rhesus macaque model. Both the DNA and rMVA components of the vaccine expressed multiple immunodeficiency virus proteins. Two DNA inoculations at 0 and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4b0fe8b5-2fed-59aa-b82f-dc9f1136b293
DOI: 10.1126/science.292.5514.69

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA VaccineDOI 10.1126/science.292.5514.69Read

Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA VaccineSemantic proximity Read

Different Patterns of Immune Responses but Similar Control of a Simian-Human Immunodeficiency Virus 89.6P Mucosal Challenge by Modified Vaccinia Virus Ankara (MVA) and DNA/MVA VaccinesSemantic proximity Read

Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys.Semantic proximity Read

Gene-Based Vaccination with a Mismatched Envelope Protects against Simian Immunodeficiency Virus Infection in Nonhuman PrimatesSemantic proximity Read

Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251).Semantic proximity Read

Broad Immunogenicity of a Multigene, Multiclade HIV‐1 DNA Vaccine Boosted with Heterologous HIV‐1 Recombinant Modified Vaccinia Virus AnkaraSemantic proximity Read

Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunitySemantic proximity Read

Protection from viral rebound after therapeutic vaccination with an adjuvanted DNA vaccine is associated with SIV-specific polyfunctional CD8 T cells in the blood and mesenteric lymph nodesSemantic proximity Read

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trialSemantic proximity Read

Control of Heterologous Simian Immunodeficiency Virus SIV smE660 Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in MacaquesSemantic proximity Read

Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeysSemantic proximity Read

Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteersSemantic proximity Read